Wedbush Has Bullish Forecast for PepGen FY2028 Earnings

PepGen Inc. (NASDAQ:PEPG) – Equities research analysts at Wedbush increased their FY2028 earnings per share (EPS) estimates for PepGen in a research report issued to clients and investors on Monday, December 16th. Wedbush analyst L. Chico now forecasts that the company will earn ($1.85) per share for the year, up from their prior forecast of ($2.08). Wedbush currently has a “Outperform” rating and a $12.00 target price on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.84) per share.

Other research analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $26.00 price target on shares of PepGen in a research report on Friday, November 8th. Bank of America lowered shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a report on Monday, December 16th.

PepGen Stock Performance

NASDAQ PEPG opened at $3.63 on Thursday. PepGen has a fifty-two week low of $2.90 and a fifty-two week high of $19.30. The firm has a market capitalization of $118.32 million, a P/E ratio of -1.22 and a beta of 1.56. The stock’s fifty day moving average is $5.96 and its two-hundred day moving average is $10.33.

Institutional Investors Weigh In On PepGen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Barclays PLC increased its position in shares of PepGen by 318.7% during the 3rd quarter. Barclays PLC now owns 21,971 shares of the company’s stock worth $189,000 after purchasing an additional 16,723 shares during the last quarter. XTX Topco Ltd acquired a new position in PepGen in the third quarter valued at about $130,000. Jane Street Group LLC boosted its stake in PepGen by 29.1% during the third quarter. Jane Street Group LLC now owns 27,748 shares of the company’s stock worth $237,000 after buying an additional 6,254 shares during the period. Wellington Management Group LLP increased its position in shares of PepGen by 76.9% during the third quarter. Wellington Management Group LLP now owns 40,517 shares of the company’s stock valued at $346,000 after acquiring an additional 17,618 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of PepGen by 331.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after acquiring an additional 1,794,641 shares during the period. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.